{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=19",
    "query": {
      "condition": "Congenital Defects",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 10850,
    "total_pages": 1085,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Defects&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T17:58:03.739Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00602225",
      "title": "Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Promyelocytic Leukemia (M3)",
        "Recurrent Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "clofarabine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2007-12",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00602225"
    },
    {
      "nct_id": "NCT01707290",
      "title": "Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ivacaftor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2013-02",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01707290"
    },
    {
      "nct_id": "NCT07050810",
      "title": "Thera-Clean® Microbubbles System in Patients With Skin Diseases",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa",
        "Ichthyosis",
        "Atopic Dermatitis",
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "TheraClean",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-01-13",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07050810"
    },
    {
      "nct_id": "NCT04470713",
      "title": "Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "GM1 Gangliosidosis",
        "GM2 Gangliosidosis",
        "Gaucher Disease, Type 2",
        "Tay-Sachs Disease",
        "AB Variant Gangliosidosis GM2",
        "Sandhoff Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Months and older"
      },
      "enrollment_count": 226,
      "start_date": "2019-07-31",
      "completion_date": "2021-10-30",
      "has_results": false,
      "last_update_posted_date": "2021-11-08",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04470713"
    },
    {
      "nct_id": "NCT02951182",
      "title": "A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "TEZ",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        },
        {
          "name": "VX-440",
          "type": "DRUG"
        },
        {
          "name": "Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2016-10",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2020-08-28",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02951182"
    },
    {
      "nct_id": "NCT05445323",
      "title": "Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Friedreich Ataxia",
        "Cardiomyopathy, Secondary"
      ],
      "interventions": [
        {
          "name": "Low dose LX2006",
          "type": "GENETIC"
        },
        {
          "name": "Mid Dose LX2006",
          "type": "GENETIC"
        },
        {
          "name": "High Dose LX2006",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Lexeo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-08-24",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Tampa, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05445323"
    },
    {
      "nct_id": "NCT01264276",
      "title": "Telemedicine Approaches to Evaluating Acute-phase ROP",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinopathy of Prematurity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "32 Weeks",
        "maximum_age": "40 Weeks",
        "sex": "ALL",
        "summary": "32 Weeks to 40 Weeks"
      },
      "enrollment_count": 269,
      "start_date": "2011-07",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-02-04",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 11,
      "location_summary": "Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 8 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264276"
    },
    {
      "nct_id": "NCT00004982",
      "title": "Combination Iron Chelation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Iron Overload",
        "Thalassemia"
      ],
      "interventions": [
        {
          "name": "Combination Iron Chelation Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-12",
      "completion_date": "2002-11",
      "has_results": false,
      "last_update_posted_date": "2010-01-14",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004982"
    },
    {
      "nct_id": "NCT00538785",
      "title": "A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Heart Disease"
      ],
      "interventions": [
        {
          "name": "Motavizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Palivizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "Up to 24 Months"
      },
      "enrollment_count": 1236,
      "start_date": "2005-10",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2012-02-16",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 30,
      "location_summary": "Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538785"
    },
    {
      "nct_id": "NCT06891443",
      "title": "Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leber Congenital Amaurosis 10",
        "Blindness",
        "Leber Congenital Amaurosis",
        "Sensation Disorders",
        "Vision Disorder",
        "Neurological Manifestations",
        "Eye Diseases, Hereditary",
        "Eye Diseases",
        "Eye Disorders Congenital",
        "Retinal Disease"
      ],
      "interventions": [
        {
          "name": "sepofarsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo IVT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2025-06-04",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-19T17:58:03.739Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06891443"
    }
  ]
}